AnGes MG Inc. | Income Statement

Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
491,311.00
909,922.00
430,154.00
514,269.00
365,183.00
610,050
Cost of Goods Sold (COGS) incl. D&A
179,717.00
182,150.00
213,008.00
232,352.00
201,488.00
191,179
Gross Income
311,594.00
727,772.00
217,146.00
281,917.00
163,695.00
418,871
SG&A Expense
1,674,745.00
3,001,657.00
4,389,131.00
4,790,736.00
3,441,354.00
3,422,259
EBIT
1,363,151.00
2,273,885.00
4,171,985.00
4,615,472.00
3,288,681.00
3,065,254
Unusual Expense
28,004.00
37,714.00
34,789.00
42,117.00
568,019.00
62,017
Non Operating Income/Expense
11,806.00
121,961.00
81,521.00
39,978.00
112,142.00
1,180
Pretax Income
1,402,184.00
2,357,614.00
4,124,150.00
4,760,670.00
3,744,187.00
3,003,002
Income Tax
7,502.00
11,591.00
19,185.00
16,110.00
20,512.00
6,372
Consolidated Net Income
1,409,686.00
2,369,205.00
4,143,335.00
4,776,780.00
3,764,699.00
2,996,629
Net Income
1,409,686.00
2,369,205.00
4,143,335.00
4,776,780.00
3,764,699.00
2,996,629
Net Income After Extraordinaries
1,409,686.00
2,369,205.00
4,143,335.00
4,776,780.00
3,764,699.00
2,996,629
Net Income Available to Common
1,409,686.00
2,369,205.00
4,143,335.00
4,776,780.00
3,764,699.00
2,996,629
EPS (Basic)
39.77
62.12
74.53
75.29
49.38
34.46
Basic Shares Outstanding
35,447.10
38,140.20
55,595.70
63,443.50
76,238.30
86,957.80
EPS (Diluted)
39.77
62.12
74.53
75.29
49.38
34.46
Diluted Shares Outstanding
35,447.10
38,140.20
55,595.70
63,443.50
76,238.30
86,957.80
EBITDA
1,303,034.00
2,227,938.00
4,123,002.00
4,548,166.00
3,259,329.00
3,057,394
Other Operating Expense
-
-
-
106,653.00
11,022.00
61,866
Non-Operating Interest Income
777.00
518.00
1,103.00
531.00
201.00
1,405
Equity in Affiliates (Pretax)
-
-
-
-
171.00
7

About AnGes MG

View Profile
Address
Saito Bio-Incubator 1F
Osaka Osaka 567
Japan
Employees -
Website http://www.anges.co.jp
Updated 07/08/2019
AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations.